CytomX Therapeutics, Inc.
CTMXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, CytomX Therapeutics, Inc. (CTMX) is listed under Biotechnology. The company carries a $505.5M market cap, placing it firmly in the small-cap category. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
Market Cap
$505.5M
Beta
2.20
P/E (TTM)
—
P/E (Fwd)
-4.93
EPS (TTM)
$-0.48
EPS (Fwd)
$-0.47
ROE
-37.8%
ROA
-19.6%
Cash
$330.3M
Total Debt
$5.7M
Free CF
-$75.2M
52W Change
-28.8%
Annual Financials
Cash vs Debt
Where CTMX stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, CTMX finished 38.23% below its 150-day moving average ($3.61) and 44.11% below its 200-day moving average ($3.99). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CTMX overbought or oversold?
At the October 15, 2026 close, CTMX's RSI(14) was 20.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $330.3M in cash comfortably exceeding the $5.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$75.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -37.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $53.2M (2022) to $76.2M (2025), reflecting a 43% increase over the period.
CytomX Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for CytomX Therapeutics, Inc. and its sector.